Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT
Observational analysis shows 2-year survival rates of 20.5% in patients with TP53-mutated AML, suggesting graft-versus-host disease management challenges.
Key Points
Overall survival at 2 years was 20.5% for patients with TP53-mutated AML receiving allogeneic transplantation, indicating a need for better strategies.
Analysis included 183 adults with acute myeloid leukemia, where 141 experienced primary induction failure, pointing to treatment difficulties.
Transplantation methods varied, with significant use of anti-thymocyte globulin for graft-versus-host disease prophylaxis among 107 patients.
Results underline the urgent need for novel therapies to tackle the high relapse incidence and improve outcomes for this patient group.